The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Kentucky leads the nation with 21 prescriptions per 1,000 residents, reflecting its 36.5% obesity rate and robust healthcare access.

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...